Lexeo Therapeutics, Inc. (LXEO) stock
LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.85−0.38 (-11.61%)
Close on Nov 17, 2026Market cap $234.24MP/E –Yield –
Lexeo Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Lexeo Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $66.64M, down 9.6% year over year. For fiscal 2025 it was $63.80M, down 13.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.80M | -13.9% |
| FY2024 | Dec 31, 2024 | $74.09M | +39.5% |
| FY2023 | Dec 31, 2023 | $53.13M | +8.1% |
| FY2022 | Dec 31, 2022 | $49.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.03M | +29.3% |
| Q1 FY2026 | Mar 31, 2026 | $15.70M | -8.5% |
| Q4 FY2025 | Dec 31, 2025 | $16.21M | -11.7% |
| Q3 FY2025 | Sep 30, 2025 | $15.70M | -33.0% |
| Q2 FY2025 | Jun 30, 2025 | $14.72M | -11.1% |
| Q1 FY2025 | Mar 31, 2025 | $17.17M | +9.1% |
| Q4 FY2024 | Dec 31, 2024 | $18.37M | +123.7% |
| Q3 FY2024 | Sep 30, 2024 | $23.42M | +35.8% |
| Q2 FY2024 | Jun 30, 2024 | $16.56M | +47.4% |
| Q1 FY2024 | Mar 31, 2024 | $15.74M | -4.2% |
| Q4 FY2023 | Dec 31, 2023 | $8.21M | -27.9% |
| Q3 FY2023 | Sep 30, 2023 | $17.25M | +12.3% |
| Q2 FY2023 | Jun 30, 2023 | $11.24M | – |
| Q1 FY2023 | Mar 31, 2023 | $16.44M | – |
| Q4 FY2022 | Dec 31, 2022 | $11.39M | – |
| Q3 FY2022 | Sep 30, 2022 | $15.36M | – |
See a number that looks wrong?